TipRanks - 2025-05-17 16:30
JonesResearch downgraded Acrivon Therapeutics (ACRV) to Hold from Buy without a price target Investors may now be focused on ACR-2316 as a way to re-validate the company’s tumor-selection platform, the analyst tells investors in a research note. The firm prefers to wait for initial data from ACR-2316 in the second half of 2025 and more meaningful data in 2026 before recommending the shares. Jones would like to see some “real de-risking clinical data to comfortably” value Acrivon’s biomarker-base